Phadia launches new diagnostic reference laboratory

Phadia, a developer and marketer of blood test systems, has launched the Phadia Immunology Reference Laboratory, or PiRL, the result of a research collaboration between the company and National Jewish Health.

According to Phadia, PiRL will help advance the understanding of immunology by providing component-resolved diagnostics (CRD) at the molecular level with ImmunoCAP specific IgE (sIgE) blood test technology.

Designed for use by clinical investigators and specialists in the field of immunology, PiRL CRD characterizes a person’s sensitization pattern at the molecular level. Used in conjunction with traditional ImmunoCAP sIgE testing, ImmunoCAP CRD will enable clinicians to assess a patient’s relative risk for allergy and severe reactions, said Phadia.

PiRL is housed at Phadia’s Portage, Michigan facility, and headed by medical director Henry Homburger, who brings to PiRL a reputation for excellence in precision assay technology that optimizes diagnosis and enhances patient care in immunology, the company noted.

Michael Land, president of Phadia US, said: We are excited about the opportunity for Phadia and National Jewish Health to collaborate in the areas of education and research through the introduction of this new reference laboratory. By providing such advanced diagnostic services for personalized patient care and research, we will one day be able to extend this understanding to a broader universe of clinicians, researchers and patients.